Health
China’s Sinovac reports mixed findings in early coronavirus vaccine trials – The Washington Post
Study found the vaccine candidate produced a quick immune response but lower levels of antibodies than in recovered coronavirus patients.
These early results put Sinovac on the back foot to prove its vaccine is effective in ongoing Phase 3 trials.
That is a concern, said Thomas Campbell, associate dean for clinical research at the University of Colorado, of the low antibody levels in Sinovacs Phase 2 trial. Its an important point here, in terms of comparing this vaccine to, for instance, the Moderna and Pfizer vaccines.
As the world awaits a coronavirus vaccine, some in China get early doses
Indonesia, the worlds fourth-most populous…
-
General22 hours agoEmergency operation underway after reports of bodies north-east of Falls Creek
-
Noosa News23 hours agoMan arrested after gaining ‘unauthorised’ access to Amberley RAAF base
-
Noosa News24 hours agoExclusion zone declared as bushfire sparks major emergency response near Brisbane
-
Noosa News22 hours agoBroncos and Roosters set for ‘Queensland versus NSW rivalry’ in NRLW grand final